Group Therapy Compared With Educational Materials in Patients With Prostate Cancer
Launched by GARY MORROW · Jan 26, 2003
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
* Determine the feasibility of providing group support, and evaluate the effect of supportive-expressive group therapy vs. written educational material on the psychological health and quality of life of men with stage I/II prostate cancer.
OUTLINE: Patients are stratified by prior hormonal therapy.
Patients continue standard oncologic treatment concurrently with supportive-expressive group therapy.
Supportive-expressive group therapy consists of twelve 90-minute weekly meetings with 8-12 members and 2 cotherapists and is based on the following themes: building bonds, express...
Gender
MALE
Eligibility criteria
- DISEASE CHARACTERISTICS:
- • Biopsy-proven prostate cancer diagnosed within 1 year prior to entry
- • Clinical stage I/II (T1b-c or T2, N0 or Nx, M0) disease
- • Pathologic local upstaging (e.g., to T3) allowed
- • No Nx disease if pathologic or partial pathologic (e.g., lymph node biopsy or dissection) staging performed
- • No major psychiatric illness requiring hospitalization or medication other than depression or anxiety for less than 1 year
- • No second malignancy within 10 years except nonmelanomatous skin cancer
- • Clinical follow-up by a urologist, medical oncologist, or radiation therapist required at least semi-annually
- PATIENT CHARACTERISTICS:
- • Age
- • Not specified
- • Performance status
- • Not specified
- • Life expectancy
- • Not specified
- • Hematopoietic
- • Not specified
- • Hepatic
- • Not specified
- • Renal
- • Not specified
- • Other
- • See Disease Characteristics
- PRIOR CONCURRENT THERAPY:
- • Biologic therapy
- • Not specified
- • Chemotherapy
- • Not specified
- • Endocrine therapy
- • Not specified
- • Radiotherapy
- • Not specified
- • Surgery
- • Not specified
About Gary Morrow
Gary Morrow is a seasoned clinical trial sponsor with extensive experience in the pharmaceutical and biotechnology sectors. Committed to advancing medical research, Morrow specializes in the design and management of innovative clinical trials aimed at evaluating new therapies and improving patient outcomes. With a focus on rigorous scientific standards and regulatory compliance, the organization collaborates with leading research institutions and healthcare professionals to facilitate the development of groundbreaking treatments. Morrow’s dedication to excellence and ethical practices positions it as a trusted partner in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wichita, Kansas, United States
Kalamazoo, Michigan, United States
Columbus, Ohio, United States
Phoenix, Arizona, United States
Tacoma, Washington, United States
Stanford, California, United States
Rochester, New York, United States
Patients applied
Trial Officials
Gary R. Morrow, PhD, MS
Study Chair
James P. Wilmot Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials